Kedar A, Mayhew E G, Moore R H, Murphy G P
Oncology. 1981;38(5):311-4. doi: 10.1159/000225577.
The potential prolongation of survival of actinomycin D entrapped in liposomes was examined in Balb C/Cr mice inoculated intrarenally with renal cell adenocarcinoma. There were five groups of animals: group A, a control group, received phosphate-buffered saline 0.3 cm3 i.p.; group B received free actinomycin D 300 micrograms/kg i.p.; group C received liposomes containing actinomycin D 300 micrograms/kg i.p.; group D received a mixture of free actinomycin D 300 micrograms/kg and empty liposomes i.p.; group E received empty liposomes i.p. The best median survival was of group D (free drug) - 54 days followed by group C (liposome entrapped actinomycin D) 45.2 days and group E (a mixture of free and entrapped actinomycin D) - 42 days. In vitro studies utilizing cell lines obtained from the tumor showed no statistical difference in ID50 or in cytotoxicity between the cells treated with free actinomycin D and those treated with liposomes containing drug.
在经肾内接种肾细胞腺癌的Balb C/Cr小鼠中,研究了包裹在脂质体中的放线菌素D延长生存期的潜力。实验动物分为五组:A组为对照组,腹腔注射0.3 cm³磷酸盐缓冲盐水;B组腹腔注射游离放线菌素D,剂量为300微克/千克;C组腹腔注射含放线菌素D的脂质体,剂量为300微克/千克;D组腹腔注射游离放线菌素D(300微克/千克)与空脂质体的混合物;E组腹腔注射空脂质体。生存期中位数最长的是D组(游离药物组)——54天,其次是C组(包裹放线菌素D的脂质体组)——45.2天,E组(游离和包裹的放线菌素D混合物组)——42天。利用从肿瘤中获取的细胞系进行的体外研究表明,用游离放线菌素D处理的细胞与用含药脂质体处理的细胞在半数抑制浓度(ID50)或细胞毒性方面无统计学差异。